Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Sodium oxybate: updates and correction to previously published safety data.

Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL.

J Clin Sleep Med. 2011 Aug 15;7(4):415-6. doi: 10.5664/JCSM.1214. No abstract available.

2.

Sodium oxybate post-marketing surveillance.

Feldman NT.

J Clin Sleep Med. 2011 Aug 15;7(4):417. doi: 10.5664/JCSM.1216. No abstract available.

3.

Xyrem (sodium oxybate) postmarketing adverse event reporting system.

Wang YG.

Sleep Med. 2010 Jun;11(6):595; author reply 595-6. doi: 10.1016/j.sleep.2010.02.003. Epub 2010 Apr 1. No abstract available.

PMID:
20362501
4.

From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy.

Fuller DE, Hornfeldt CS.

Pharmacotherapy. 2003 Sep;23(9):1205-9.

PMID:
14524654
5.

Response to Editorial: "Xyrem safety: The debate continues".

Zvosec DL, Smith SW.

Sleep Med. 2010 Jan;11(1):108; author reply 108-9. doi: 10.1016/j.sleep.2009.08.004. Epub 2009 Dec 2. No abstract available.

PMID:
19959395
6.

Sodium oxybate is an effective and safe treatment for narcolepsy.

Lammers GJ, Bassetti C, Billiard M, Black J, Broughton R, Dauvilliers Y, Ferini Strambi L, Garcia-Borreguero D, Goswami M, Högl B, Iranzo A, Jennum P, Khatami R, Lecendreux M, Mayer G, Mignot E, Montplaisir J, Nevsimalova S, Peraita-Adrados R, Plazzi G, Scammell T, Silber M, Sonka K, Tafti M, Thorpy M.

Sleep Med. 2010 Jan;11(1):105-6; author reply 106-8. doi: 10.1016/j.sleep.2009.08.003. Epub 2009 Oct 20. No abstract available.

PMID:
19846338
7.

Sodium oxybate for cataplexy.

Lemon MD, Strain JD, Farver DK.

Ann Pharmacother. 2006 Mar;40(3):433-40; quiz 581-2. Epub 2006 Feb 28. Review.

PMID:
16507620
8.

The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects.

Borgen LA, Okerholm R, Morrison D, Lai A.

J Clin Pharmacol. 2003 Jan;43(1):59-65.

PMID:
12520629
9.

A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.

George CF, Feldman N, Inhaber N, Steininger TL, Grzeschik SM, Lai C, Zheng Y.

Sleep Med. 2010 Jan;11(1):38-42. doi: 10.1016/j.sleep.2009.06.006. Epub 2009 Nov 7.

PMID:
19897413
10.
11.

The new "Mickey Finn specials"--should GHB and ketamine be banned?

Li J.

J Am Pharm Assoc (Wash). 1999 Jul-Aug;39(4):442-3. No abstract available.

PMID:
10467808
12.

Comment on "The abrupt cessation of therapeutically administered sodium oxybate (GHB) may cause withdrawal symptoms".

Zvosec DL, Smith SW.

J Toxicol Clin Toxicol. 2004;42(1):121-3; author reply 125-7. Review. No abstract available.

PMID:
15083950
13.

Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial.

Russell IJ, Perkins AT, Michalek JE; Oxybate SXB-26 Fibromyalgia Syndrome Study Group.

Arthritis Rheum. 2009 Jan;60(1):299-309. doi: 10.1002/art.24142.

14.

Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.

[No authors listed]

Prescrire Int. 2007 Jun;16(89):98-101.

PMID:
17582923
16.

Sodium oxybate for narcolepsy.

Scharf MB.

Expert Rev Neurother. 2006 Aug;6(8):1139-46. Review.

PMID:
16893342
17.

Coma-inducing drug GHB may be reclassified.

Marwick C.

JAMA. 1997 May 21;277(19):1505-6. No abstract available.

PMID:
9153353
18.

Market watch: upcoming market catalysts in Q4 2010.

Rosenthal J.

Nat Rev Drug Discov. 2010 Oct;9(10):755. doi: 10.1038/nrd3286. No abstract available.

PMID:
20885399
19.

Rave drugs: pharmacological considerations.

Hornfeldt CS.

AANA J. 2004 Oct;72(5):334-5; author reply 335. No abstract available.

PMID:
15529726
20.

Supplemental Content

Support Center